Starch-based hydrogel for administration of therapeutic anticancer agents
OwnerElizabeth Diana Barkerinventor
Life of this patent
Estimating the term…
Abstract
A starch-based injectable hydrogel system for localized cancer treatment. The pre-formed hydrogel delivers chemotherapeutic drugs (such as doxorubicin) and/or medical radionuclides directly to tumor sites while minimizing systemic exposure. The composition uses dimethyl sulfoxide as a solvent and can be stored in pre-filled syringes for clinical use. Key advantages include >90% drug retention, sustained local delivery, and compatibility with image-guided injection techniques. The system is particularly suitable for pediatric brain tumors and other solid tumors requiring localized high-dose therapy.
Claims26
A composition comprising:
- a starch-derived polymer forming a hydrogel matrix;
- a solvent comprising dimethyl sulfoxide, an aqueous solvent selected from phosphate buffered saline or sodium chloride solution, or a combination thereof;
- and
- a chemotherapeutic agent comprising
- doxorubicin in its free base form or
- a compound that is insoluble in water and substantially soluble in dimethyl sulfoxide,
- wherein the composition may be a pre-formed injectable hydrogel formulation comprising the therapeutic agent prior to administration.
A composition comprising:
- a starch-based hydrogel comprising a polymer matrix;
- a solvent comprising dimethyl sulfoxide, an aqueous solvent selected from phosphate buffered saline or sodium chloride solution, or a combination thereof;
- and
- a radionuclide selected from
- an alpha-emitting radionuclide,
- a beta-emitting radionuclide, or
- a gamma-emitting radionuclide,
- wherein the composition is a pre-formed injectable hydrogel formulation comprising the radionuclide prior to administration.
A composition comprising:
- a starch-derived polymer forming a hydrogel matrix;
- a solvent comprising dimethyl sulfoxide, an aqueous solvent selected from phosphate buffered saline or sodium chloride solution, or a combination thereof;
- and
- a therapeutic agent selected from a chemotherapeutic agent or a radionuclide, wherein the composition is a pre-formed injectable hydrogel formulation that is formed prior to administration;
- optionally wherein the chemotherapeutic agent comprises doxorubicin in its free base form or a compound that is insoluble in water and soluble in dimethyl sulfoxide;
- and
- optionally wherein the radionuclide is selected from an alpha-emitting radionuclide, a beta-emitting radionuclide, or a gamma-emitting radionuclide, and comprises cerium-144, cerium-141, actinium-225, thorium-227, lutetium-177, terbium-161, yttrium-90, or indium-111.
A method of treating a solid tumor in a subject comprising:
- administering to the solid tumor a composition comprising:
- a starch-based hydrogel comprising a network of starch polymer chains crosslinked using a crosslinking agent;
- a solvent comprising dimethyl sulfoxide;
- and
- a therapeutic agent selected from a chemotherapeutic agent or a radionuclide, wherein the composition is a pre-formed injectable hydrogel formulation that is formed prior to administration;
- optionally wherein the chemotherapeutic agent comprises doxorubicin in its free base form;
- optionally wherein the radionuclide is selected from cerium-144, cerium-141, actinium-225, thorium-227, lutetium-177, or terbium-161;
- and optionally wherein the tumor comprises a pediatric brain tumor.
Dependencies are inferred from the claim text.